Albumin-based cancer therapeutics for intraperitoneal drug delivery: a review

References

• Al Rawahi T, Lopes AD, Bristow RE, et al. (2013). Surgical cytoreduction for recurrent epithelial ovarian cancer. Cochrane Database Syst Rev CD008765.
   PubMed Web of Science ®Google Scholar
• An FF, Deng ZJ, Ye J, et al. (2014). Aggregation-induced near-infrared absorption of squaraine dye in an albumin nanocomplex for photoacoustic tomography in vivo. ACS Appl Mater Interfaces 6:17985–92.
   PubMed Web of Science ®Google Scholar
• An FF, Zhang XH. (2017). Strategies for preparing albumin-based nanoparticles for multifunctional bioimaging and drug delivery. Theranostics 7:3667–89.
   PubMed Web of Science ®Google Scholar
• André N, Carré M, Pasquier E. (2014). Metronomics: towards personalized chemotherapy? Nat Rev Clin Oncol 11:413–31.
   PubMed Web of Science ®Google Scholar
• Arroyo V, García-Martinez R, Salvatella X. (2014). Human serum albumin, systemic inflammation, and cirrhosis. J Hepatol 61:396–407.
   PubMed Web of Science ®Google Scholar
• Bodega F, Zocchi L, Agostoni E. (2002). Albumin transcytosis in mesothelium. Am J Physiol Lung Cell Mol Physiol 282:L3–L11.
   PubMed Web of Science ®Google Scholar
• Burger AM, Hartung G, Stehle G, et al. (2001). Pre-clinical evaluation of a methotrexate–albumin conjugate (MTX-HSA) in human tumor xenografts in vivo. Int J Cancer 92:718–24.
   PubMed Web of Science ®Google Scholar
• Carlier C, Hoorens A, De Clercq K, et al. (2018). Preclinical activity of two paclitaxel nanoparticle formulations after IP administration in ovarian cancer xenografts. Regional Cancer Therapies 13th International symposium, Abstracts. Presented at the 13th International symposium on Regional Cancer Therapies (SSO 2018).
   Google Scholar
• Carlier C, Mathys A, Jaeghere ED, et al. (2017). Tumour tissue transport after intraperitoneal anticancer drug delivery. Int J Hyperthermia 33:534–42.
   PubMed Web of Science ®Google Scholar
• Ceelen WP, Bracke ME. (2009). Peritoneal minimal residual disease in colorectal cancer: mechanisms, prevention, and treatment. Lancet Oncol 10:72–9.
   PubMed Web of Science ®Google Scholar
• Ceelen WP, Flessner MF. (2010). Intraperitoneal therapy for peritoneal tumors: biophysics and clinical evidence. Nat Rev Clin Oncol 7:108–15.
   PubMed Web of Science ®Google Scholar
• Chatterjee M, Ben-Josef E, Robb R, et al. (2017). Caveolae-mediated endocytosis is critical for albumin cellular uptake and response to albumin-bound chemotherapy. Cancer Res 77:5925–37.
   PubMed Web of Science ®Google Scholar
• Chen CC, Li JJ, Guo NH, et al. E (2019). Evaluation of the biological behavior of a gold nanocore-encapsulated human serum albumin nanoparticle (Au@HSANP) in a CT-26 tumor/ascites mouse model after intravenous/intraperitoneal administration. Int J Mol Sci 20:217.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. (2019a). A Phase 1 Trial of ABI-011 in Patients With Advanced Solid Tumors or Lymphomas. Available at: https://clinicaltrials.gov/ct2/show/NCT01163071 [last accessed 23 Sep 2019].
   Google Scholar
• ClinicalTrials.gov. (2019b). ABI-008 Trial in Patients With Hormone-refractory Prostate Cancer. Available at: https://clinicaltrials.gov/ct2/show/NCT00477529 [last accessed 23 Sep 2019].
   Google Scholar
• ClinicalTrials.gov. (2019c). ABI-009 (Nab-Rapamycin) in Recurrent High Grade Glioma and Newly Diagnosed Glioblastoma. Available at: https://clinicaltrials.gov/ct2/show/NCT03463265 [last accessed 23 Sep 2019].
   Google Scholar
• Coccolini F, Acocella F, Morosi L, et al. (2017). High penetration of paclitaxel in abdominal wall of rabbits after hyperthermic intraperitoneal administration of Nab-paclitaxel compared to standard paclitaxel formulation. Pharm Res 34:1180–6.
   PubMed Web of Science ®Google Scholar
• Coccolini F. (2013). Peritoneal carcinomatosis. World J Gastroenterol 19:6979.
   PubMed Web of Science ®Google Scholar
• Cristea MC, Frankel P, Synold T, et al. (2019). A phase I trial of intraperitoneal nab-paclitaxel in the treatment of advanced malignancies primarily confined to the peritoneal cavity. Cancer Chemother Pharmacol 83:589–98.
   PubMed Web of Science ®Google Scholar
• Curry S, Mandelkow H, Brick P, Franks N. (1998). Crystal structure of human serum albumin complexed with fatty acid reveals an asymmetric distribution of binding sites. Nat Struct Biol 5:827–35.
   PubMed Web of Science ®Google Scholar
• D’Cruz O, Piacente M, Trieu V, et al. (2010). Abstract 2617: Cardiovascular and CNS safety profile of ABI-013, a novel nanoparticle albumin-bound (nab) analog of docetaxel. Cancer Res 70:2617.
   Google Scholar
• Dakwar GR, Shariati M, Willaert W, et al. (2017). Nanomedicine-based intraperitoneal therapy for the treatment of peritoneal carcinomatosis – mission possible? Adv Drug Deliv Rev 108:13–24.
   PubMed Web of Science ®Google Scholar
• Daugirdas JT, Ing TS, Gandhi VC, et al. (1980). Kinetics of peritoneal fluid absorption in patients with chronic renal failure. J Lab Clin Med 95:351–61.
   PubMed Web of Science ®Google Scholar
• de Lima Vazquez V, Stuart OA, Mohamed F, Sugarbaker PH. (2003). Extent of parietal peritonectomy does not change intraperitoneal chemotherapy pharmacokinetics. Cancer Chemother Pharmacol 52:108–12.
   PubMed Web of Science ®Google Scholar
• Dedrick RL, Flessner MF. (1997). Pharmacokinetic problems in peritoneal drug administration: tissue penetration and surface exposure. J Natl Cancer Inst 89:480–7.
   PubMed Web of Science ®Google Scholar
• Dedrick RL, Myers CE, Bungay PM, DeVita VT. (1978). Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treat Rep 62:1–11.
   PubMedGoogle Scholar
• Desai N. (2008). Nab technology: a drug delivery platform utilising endothelial gp60 receptor-based transport and tumour-derived SPARC for targeting. Drug delivery report winter 2007/2008 8.
   Google Scholar
• Desai N. (2016) Nanoparticle albumin-bound paclitaxel (Abraxane®). In: Otagiri M, Chuang VTG, eds. Albumin in medicine: pathological and clinical applications. Singapore: Springer, 101–19.
   Google Scholar
• Di Stefano G, Fiume L, Baglioni M, et al. (2008). Efficacy of doxorubicin coupled to lactosaminated albumin on rat hepatocellular carcinomas evaluated by ultrasound imaging. Dig Liver Dis 40:278–84.
   PubMedGoogle Scholar
• Dou WF, Lei JY, Zhang LF, et al. (2008). Expression, purification, and characterization of recombinant human serum albumin fusion protein with two human glucagon-like peptide-1 mutants in Pichia pastoris. Protein Expr Purif 61:45–9.
   PubMed Web of Science ®Google Scholar
• Esquivel J. (2010). Current status of colorectal cancer with peritoneal carcinomatosis. Ann Surg Oncol 17:1968–9.
   PubMed Web of Science ®Google Scholar
• Evans WE, Crom WR, Abromowitch M, et al. (1986). Clinical pharmacodynamics of high-dose methotrexate in acute lymphocytic leukemia. N Engl J Med 314:471–7.
   PubMed Web of Science ®Google Scholar
• Fan R, Tong A, Li X, et al. (2015). Enhanced antitumor effects by docetaxel/LL37-loaded thermosensitive hydrogel nanoparticles in peritoneal carcinomatosis of colorectal cancer. Int J Nanomedicine 10:7291–305.
   PubMed Web of Science ®Google Scholar
• Flessner MF, Dedrick RL, Schultz JS. (1985). Exchange of macromolecules between peritoneal cavity and plasma. Am J Physiol Heart Circ Physiol 248:H15–H25.
   PubMed Web of Science ®Google Scholar
• Flessner MF, Fenstermacher JD, Dedrick RL, Blasberg RG. (1985). A distributed model of peritoneal-plasma transport: tissue concentration gradients. Am J Physiol Renal Physiol 248:F425–F435.
   PubMedGoogle Scholar
• Flessner MF, Parker RJ, Sieber SM. (1983). Peritoneal lymphatic uptake of fibrinogen and erythrocytes in the rat. Am J Physiol 244:H89–96.
   PubMedGoogle Scholar
• Flessner MF, Schwab A. (1996). Pressure threshold for fluid loss from the peritoneal cavity. Am J Physiol Renal Physiol 270:F377–F390.
   Web of Science ®Google Scholar
• Flessner MF. (2005). The transport barrier in intraperitoneal therapy. Am J Physiol Renal Physiol 288:F433–F442.
   PubMed Web of Science ®Google Scholar
• Gardner ER, Dahut WL, Scripture CD, et al. (2008). Randomized crossover pharmacokinetic study of solvent-based paclitaxel and nab-paclitaxel. Clin Cancer Res 14:4200–5.
   PubMed Web of Science ®Google Scholar
• Goodman MD, McPartland S, Detelich D, Saif MW. (2016). Chemotherapy for intraperitoneal use: a review of hyperthermic intraperitoneal chemotherapy and early post-operative intraperitoneal chemotherapy. J Gastrointest Oncol 7:13.
   Web of Science ®Google Scholar
• Gotloib L, Shostak A. (1995). Endocytosis and transcytosis of albumin gold through mice peritoneal mesothelium. Kidney Int 47:1274–84.
   PubMed Web of Science ®Google Scholar
• Grass F, Vuagniaux A, Teixeira-Farinha H, et al. (2017). Systematic review of pressurized intraperitoneal aerosol chemotherapy for the treatment of advanced peritoneal carcinomatosis. Br J Surg 104:669–78.
   PubMed Web of Science ®Google Scholar
• Graversen M, Detlefsen S, Pfeiffer P, et al. (2018). Severe peritoneal sclerosis after repeated pressurized intraperitoneal aerosol chemotherapy with oxaliplatin (PIPAC OX): report of two cases and literature survey. Clin Exp Metastasis 35:103–8.
   PubMed Web of Science ®Google Scholar
• Guweidhi A, Kleeff J, Adwan H, et al. (2005). Osteonectin influences growth and invasion of pancreatic cancer cells. Ann Surg 242:224–34.
   PubMed Web of Science ®Google Scholar
• Hartung G, Stehle G, Sinn H, et al. (1999). Phase I trial of methotrexate-albumin in a weekly intravenous bolus regimen in cancer patients. Clin Cancer Res 5:753–9.
   PubMed Web of Science ®Google Scholar
• Hasovits C, Clarke S. (2012). Pharmacokinetics and pharmacodynamics of intraperitoneal cancer chemotherapeutics. Clin Pharmacokinet 51:203–24.
   PubMed Web of Science ®Google Scholar
• Helm CW, Edwards RP. (2007). Intraperitoneal cancer therapy. Totowa, NJ: Humana Press.
   Google Scholar
• Hidalgo M, Plaza C, Musteanu M, et al. (2015). SPARC expression did not predict efficacy of nab-paclitaxel plus gemcitabine or gemcitabine alone for metastatic pancreatic cancer in an exploratory analysis of the phase III MPACT trial. Clin Cancer Res 21:4811–8.
   PubMed Web of Science ®Google Scholar
• Hoogenboezem EN, Duvall CL. (2018). Harnessing albumin as a carrier for cancer therapies. Adv Drug Deliv Rev 130:73–89.
   PubMed Web of Science ®Google Scholar
• Infante JR, Matsubayashi H, Sato N, et al. (2007). Peritumoral fibroblast SPARC expression and patient outcome with resectable pancreatic adenocarcinoma. J Clin Oncol 25:319–25.
   PubMed Web of Science ®Google Scholar
• Kaplan RA, Markman M, Lucas WE, et al. (1985). Infectious peritonitis in patients receiving intraperitoneal chemotherapy. Am J Med 78:49–53.
   PubMed Web of Science ®Google Scholar
• Kim B, Lee C, Lee ES, et al. (2016). Paclitaxel and curcumin co-bound albumin nanoparticles having antitumor potential to pancreatic cancer. Asian J Pharm Sci 11:708–14.
   Web of Science ®Google Scholar
• Kim TH, Jiang HH, Youn YS, et al. (2011). Preparation and characterization of water-soluble albumin-bound curcumin nanoparticles with improved antitumor activity. Int J Pharm 403:285–91.
   PubMed Web of Science ®Google Scholar
• Kinoshita J, Fushida S, Tsukada T, et al. (2014). Comparative study of the antitumor activity of Nab-paclitaxel and intraperitoneal solvent-based paclitaxel regarding peritoneal metastasis in gastric cancer. Oncol Rep 32:89–96.
   PubMed Web of Science ®Google Scholar
• Klaver YLB, Simkens LHJ, Lemmens V, et al. (2012). Outcomes of colorectal cancer patients with peritoneal carcinomatosis treated with chemotherapy with and without targeted therapy. European Journal of Surgical Oncology (EJSO) 38:617–23.
   PubMed Web of Science ®Google Scholar
• Kragh-Hansen U. (1981). Molecular aspects of ligand binding to serum albumin. Pharmacol Rev 33:17–53.
   PubMed Web of Science ®Google Scholar
• Kratz F. (2008). Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles. J Control Release 132:171–83.
   PubMed Web of Science ®Google Scholar
• Kumano K, Go K, He M, Sakai T. (1996). Role of diaphragmatic, visceral, and parietal pathways in peritoneal fluid absorption in rat peritoneal dialysis. Perit Dial Int 16: S80–S83.
   PubMedGoogle Scholar
• Larsen MT, Kuhlmann M, Hvam ML, Howard KA. (2016). Albumin-based drug delivery: harnessing nature to cure disease. Mol Cell Ther 4:3.
   PubMedGoogle Scholar
• Lotze MT, Matory YL, Ettinghausen SE, et al. (1985). In vivo administration of purified human interleukin 2. II. Half life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL 2. J Immunol 135:2865–75.
   PubMed Web of Science ®Google Scholar
• Maltas E, Gubbuk IH, Yildiz S. (2016). Development of doxorubicin loading platform based albumin-sporopollenin as drug carrier. Biochem Biophys Rep 7:201–5.
   PubMedGoogle Scholar
• Melder RJ, Osborn BL, Riccobene T, et al. (2005). Pharmacokinetics and in vitro and in vivo anti-tumor response of an interleukin-2-human serum albumin fusion protein in mice. Cancer Immunol Immunother 54:535–47.
   PubMed Web of Science ®Google Scholar
• Merlot AM, Kalinowski DS, Richardson DR. (2014). Unraveling the mysteries of serum albumin - more than just a serum protein. Front Physiol 5:1–7.
   PubMed Web of Science ®Google Scholar
• Miele E, Spinelli GP, Miele E, et al. (2009). Albumin-bound formulation of paclitaxel (Abraxane; ABI-007) in the treatment of breast cancer. Int J Nanomedicine 4:99–105.
   PubMed Web of Science ®Google Scholar
• Motevalli SM, Eltahan AS, Liu L, et al. (2019). Co-encapsulation of curcumin and doxorubicin in albumin nanoparticles blocks the adaptive treatment tolerance of cancer cells. Biophys Rep 5:19–30.
   Google Scholar
• Mutsaers SE, Prêle CA, Pengelly S, Herrick SE. (2016). Mesothelial cells and peritoneal homeostasis. Fertil Steril 106:1018–24.
   PubMed Web of Science ®Google Scholar
• Osborn BL, Gu M, Grzegorzewski KJ, et al. (2004). Preliminary pharmacokinetic evaluation of Albuleukin; an interleukin-2 human serum albumin fusion protein, in solid tumor patients. AACR Meeting Abstracts 1099-b.
   Google Scholar
• Oseledchyk A, Zivanovic O. (2015). Intraoperative hyperthermic intraperitoneal chemotherapy in patients with advanced ovarian cancer. Oncology (Williston Park, NY) 29:695–701.
   PubMed Web of Science ®Google Scholar
• Pruitt FL, Brennen N, Antony L, et al. (2016). Abstract 2076: Albumin-linked proaerolysin based molecular grenades: a systemic therapeutic for disseminated castration resistant prostate cancer. Cancer Res 76:2076.
   Google Scholar
• Qi WW, Yu HY, Guo H, et al. (2015). Doxorubicin-loaded glycyrrhetinic acid modified recombinant human serum albumin nanoparticles for targeting liver tumor chemotherapy. Mol Pharmaceutics 12:675–83.
   PubMed Web of Science ®Google Scholar
• Rosenberg SA. (2001). Progress in human tumour immunology and immunotherapy. Nature 411:380–4.
   PubMed Web of Science ®Google Scholar
• Sandoval P, Jiménez-Heffernan JA, Rynne-Vidal Á, et al. (2013). Carcinoma-associated fibroblasts derive from mesothelial cells via mesothelial-to-mesenchymal transition in peritoneal metastasis. J Pathol 231:517–31.
   PubMed Web of Science ®Google Scholar
• Sharma A, Kaur A, Jain UK, et al. (2017). Stealth recombinant human serum albumin nanoparticles conjugating 5-fluorouracil augmented drug delivery and cytotoxicity in human colon cancer, HT-29 cells. Colloids Surf B Biointerfaces 155:200–8.
   PubMed Web of Science ®Google Scholar
• Sjobring U, Falkenberg C, Nielsen E, et al. (1988). Isolation and characterization of a 14-kDa albumin-binding fragment of streptococcal protein G. J Immunol 140:1595–9.
   PubMed Web of Science ®Google Scholar
• Sluiter N, de Cuba E, Kwakman R, et al. (2016). Adhesion molecules in peritoneal dissemination: function, prognostic relevance and therapeutic options. Clin Exp Metastasis 33:401–16.
   PubMed Web of Science ®Google Scholar
• Solass W, Kerb R, Mürdter T, et al. (2014). Intraperitoneal Chemotherapy of Peritoneal Carcinomatosis Using Pressurized Aerosol as an Alternative to Liquid Solution: First Evidence for Efficacy. Ann Surg Oncol 21:553–9.
   PubMed Web of Science ®Google Scholar
• Stinchcombe TE. (2007). Nanoparticle albumin-bound paclitaxel: a novel Cremphor-EL®-free formulation of paclitaxel. Nanomedicine 2:415–23.
   PubMed Web of Science ®Google Scholar
• Sun C, Punia K, Mancuso A, et al. (2014). Synthesis, Characterization and Anti-Cervical Cancer Cell Properties of Bovine Serum Albumen Curcumin Conjugate. Biochem Biophys J Neutron Ther Cancer Treat 2:27–32.
   Google Scholar
• Tempfer CB. (2015). Pressurized intraperitoneal aerosol chemotherapy as an innovative approach to treat peritoneal carcinomatosis. Med Hypotheses 85:480–4.
   PubMed Web of Science ®Google Scholar
• Thomassen I, Lemmens V, Nienhuijs SW, et al. (2013). Incidence, prognosis, and possible treatment strategies of peritoneal carcinomatosis of pancreatic origin: a population-based study. Pancreas 42:72–5.
   PubMed Web of Science ®Google Scholar
• Thomassen I, van Gestel YR, van Ramshorst B, et al. (2014). Peritoneal carcinomatosis of gastric origin: a population-based study on incidence, survival and risk factors. Int J Cancer 134:622–8.
   PubMed Web of Science ®Google Scholar
• van Baal J, Van de Vijver KK, Nieuwland R, et al. (2017). The histophysiology and pathophysiology of the peritoneum. Tissue Cell 49:95–105.
   PubMed Web of Science ®Google Scholar
• Van De Sande L, Graversen M, Hubner M, et al. (2018). Intraperitoneal aerosolization of albumin-stabilized paclitaxel nanoparticles (AbraxaneTM) for peritoneal carcinomatosis – a phase I first-in-human study. Pleura Peritoneum 3:1–5.
   Web of Science ®Google Scholar
• Vis A, van der Gaast A, van Rhijn B, et al. (2002). A phase II trial of methotrexate-human serum albumin (MTX-HSA) in patients with metastatic renal cell carcinoma who progressed under immunotherapy. Cancer Chemother Pharmacol 49:342–5.
   PubMed Web of Science ®Google Scholar
• Von Hoff DD, Ramanathan RK, Borad MJ, et al. (2011). Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. J Clin Oncol 29:4548–54.
   PubMed Web of Science ®Google Scholar
• Wagner S, Rothweiler F, Anhorn MG, et al. (2010). Enhanced drug targeting by attachment of an anti αv integrin antibody to doxorubicin loaded human serum albumin nanoparticles. Biomaterials 31:2388–98.
   PubMed Web of Science ®Google Scholar
• Walker JL, Armstrong DK, Huang HQ, et al. (2006). Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group Study. Gynecol Oncol 100:27–32.
   PubMed Web of Science ®Google Scholar
• Wan X, Zheng X, Pang X, et al. (2016). Lapatinib-loaded human serum albumin nanoparticles for the prevention and treatment of triple-negative breast cancer metastasis to the brain. Oncotarget 7:34038–51.
   PubMedGoogle Scholar
• Winner KK, Steinkamp MP, Lee RJ, et al. (2016). Spatial modeling of drug delivery routes for treatment of disseminated ovarian cancer. Cancer Res 76:1320–34.
   PubMed Web of Science ®Google Scholar
• Xiao K, Luo J, Fowler WL, et al. (2009). A self-assembling nanoparticle for paclitaxel delivery in ovarian cancer. Biomaterials 30:6006–16.
   PubMed Web of Science ®Google Scholar
• Yu X, Song Y, Di Y, et al. (2016). Enhanced tumor targeting of cRGD peptide-conjugated albumin nanoparticles in the BxPC-3 cell line. Sci Rep 6:31539.
   PubMed Web of Science ®Google Scholar
• Zhao D, Zhao X, Zu Y, et al. (2010). Preparation, characterization, and in vitro targeted delivery of folate-decorated paclitaxel-loaded bovine serum albumin nanoparticles. Int J Nanomedicine 5:669–77.
   PubMed Web of Science ®Google Scholar
• Zhao P, Yin W, Wu A, et al. (2017). Dual-targeting to cancer cells and M2 macrophages via biomimetic delivery of mannosylated albumin nanoparticles for drug-resistant cancer therapy. Adv Funct Mater 27:1700403.
   Web of Science ®Google Scholar
• Zhao Y, Lv F, Chen S, et al. (2018). Caveolin-1 expression predicts efficacy of weekly nab-paclitaxel plus gemcitabine for metastatic breast cancer in the phase II clinical trial. BMC Cancer 18:1019.
   PubMed Web of Science ®Google Scholar